{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:10:10Z","timestamp":1746339010805,"version":"3.40.4"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"26","license":[{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>This study retrospectively studied transarterial chemoembolization (TACE) combined with partial splenic embolization (PSE) in the treatment of hepatocellular carcinoma (HCC) with severe hypersplenism.<\/jats:p>\n            <jats:p>Seventy patients with HCC in Barcelona Clinic Liver Cancer (BCLC) stage B or C with hypersplenism were divided into non-partial splenic embolization group (N-PSE, n\u200a=\u200a51) and partial splenic embolization group (PSE, n\u200a=\u200a19). The N-PSE group was further divided into N-PSE with mild to moderate hypersplenism (N-PSE-M, 47 cases) and N-PSE with severe hypersplenism (N-PSE-S, 4 cases).<\/jats:p>\n            <jats:p>In the PSE group, leukocytes, neutrophils, lymphocytes, and platelets were significantly increased (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05) and were significantly different from that in the N-PSE group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05). In the N-PSE group, except for a slight increase in neutrophils, other blood cells were decreased, including lymphocytes that were significantly decreased (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05). There was no significant difference in the changes of liver function between the 2 groups before and after surgery (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&gt;\u200a.05). The analysis showed a significant increase in ascites after 6\u200amonths of TACE in the N-PSE group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05). According to the follow-up results, the median overall survival (OS) in the PSE group was 24.47\u200a\u00b1\u200a3.68 (months) and progression-free survival (PFS) was 12.63\u200a\u00b1\u200a4.98 (months). Regardless of OS or PFS, the PSE group was superior to the N-PSE group and its subgroups, with a statistically significant difference in PFS between the N-PSE group and PSE group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05). Moreover, the time of extrahepatic progression was significantly earlier in the N-PSE group than in the PSE group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05). N-PSE-S group had the worst prognosis, and PFS and OS were worse than the other 2 groups, suggesting that PSE in severe hypersplenism may improve PFS and OS.<\/jats:p>\n            <jats:p>In patients with HCC and severe hypersplenism, TACE should be actively combined with PSE treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000026441","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T14:48:51Z","timestamp":1625064531000},"page":"e26441","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Effect of partial splenic embolization on transarterial chemoembolization for hepatocellular carcinoma with hypersplenism"],"prefix":"10.1097","volume":"100","author":[{"given":"Jibing","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Interventional Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinfa","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiyong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8385-222X","authenticated-orcid":false,"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengyong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Intervention Therapy, General Hospital of the Chinese People's Liberation Army, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,7,2]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"11937","DOI":"10.1073\/pnas.1613466113","article-title":"Hypoxia-activated cytotoxic agent tirapazamine enhances hepatic artery ligation-induced killing of liver tumor in HBx transgenic mice","volume":"113","author":"Lin","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ctrv.2018.11.002","article-title":"Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence","volume":"72","author":"Raoul","year":"2019","journal-title":"Cancer Treat Rev"},{"issue":"(5 suppl 1)","key":"R4-20250504","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: incidence and risk factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s002709900119","article-title":"Partial splenic embolization for hypersplenism concomitant with or after arterial embolization of hepatocellular carcinoma in 30 patients","volume":"20","author":"Han","year":"1997","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/00004424-197307000-00054","article-title":"Embolic therapy of hypersplenism","volume":"8","author":"Maddison","year":"1973","journal-title":"Investig Radiol"},{"key":"R7-20250504","first-page":"6593","article-title":"Combined treatment of hepatocellular carcinoma with partial splenic embolization and transcatheter hepatic arterial chemoembolization","volume":"13","author":"Huang","year":"2007","journal-title":"World J Gastroenterol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1872-034X.2009.00508.x","article-title":"Therapeutic benefits of partial splenic embolization for thrombocytopenia in hepatocellular carcinoma patients treated with radiofrequency ablation","volume":"39","author":"Hidaka","year":"2009","journal-title":"Hepatol Res"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s00261-018-1500-9","article-title":"Spleen enlargement assessment using computed tomography: which coefficient correlates the strongest with the real volume of the spleen?","volume":"43","author":"Kucyba\u0142a","year":"2018","journal-title":"Abdom Radiol (NY)"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.blre.2008.10.001","article-title":"Splenomegaly: investigation, diagnosis and management","volume":"23","author":"Pozo","year":"2009","journal-title":"Blood Rev"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"M166","DOI":"10.12968\/hmed.2011.72.Sup11.M166","article-title":"Splenomegaly","volume":"72","author":"Brown","year":"2011","journal-title":"Br J Hosp Med (Lond)"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/hepr.12222","article-title":"Concurrent partial splenic embolization with transcatheter arterial chemoembolization for hepatocellular carcinoma can maintain hepatic functional reserve","volume":"44","author":"Ishikawa","year":"2014","journal-title":"Hepatol Res"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.3346\/jkms.2019.34.e208","article-title":"Long-term efficacy and safety of partial splenic embolization in hepatocellular carcinoma patients with thrombocytopenia who underwent transarterial chemoembolization","volume":"34","author":"Kim","year":"2019","journal-title":"J Korean Med Sci"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.cgh.2009.02.021","article-title":"Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis","volume":"7","author":"Qamar","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00000441-200309000-00001","article-title":"Predictors and implications of severe hypersplenism in patients with cirrhosis","volume":"326","author":"Liangpunsakul","year":"2003","journal-title":"Am J Med Sci"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1072-7515(99)00294-X","article-title":"Splenectomy in patients with hepatocellular carcinoma and hypersplenism","volume":"190","author":"Sugawara","year":"2000","journal-title":"J Am Coll Surg"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jinf.2001.0904","article-title":"Risk of infection and death among post-splenectomy patients","volume":"43","author":"Bisharat","year":"2001","journal-title":"J Infect"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12865-014-0042-3","article-title":"Assessment of immune cells and function of the residual spleen after subtotal splenectomy due to splenomegaly in cirrhotic patients","volume":"15","author":"Chu","year":"2014","journal-title":"BMC Immunol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.injury.2011.05.028","article-title":"Circulating cellular and humoral elements of immune function following splenic arterial embolisation or splenectomy in trauma patients","volume":"43","author":"Walusimbi","year":"2012","journal-title":"Injury"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.3892\/mmr.2015.4171","article-title":"Effect of transcatheter arterial chemoembolization on cellular immune function and regulatory T cells in patients with hepatocellular carcinoma","volume":"12","author":"Liao","year":"2015","journal-title":"Mol Med Rep"},{"issue":"(suppl)","key":"R21-20250504","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000451015","article-title":"Immunological microenvironment of hepatocellular carcinoma and its clinical implication","volume":"92","author":"Nishida","year":"2017","journal-title":"Oncology"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1200\/JCO.2007.15.6521","article-title":"High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma","volume":"26","author":"Zhu","year":"2008","journal-title":"J Clin Oncol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"e1219828","DOI":"10.1080\/2162402X.2016.1219828","article-title":"Peritumoral stromal neutrophils are essential for c-Met-elicited metastasis in human hepatocellular carcinoma","volume":"5","author":"He","year":"2016","journal-title":"Oncoimmunology"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3748\/wjg.v13.i4.619","article-title":"Evaluation of the effect of partial splenic embolization on platelet values for liver cirrhosis patients with thrombocytopenia","volume":"13","author":"Lee","year":"2007","journal-title":"World J Gastroenterol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3892\/mmr.2013.1856","article-title":"The long-term effects of splenectomy and subsequent interferon therapy in patients with HCV-related liver cirrhosis","volume":"9","author":"Inagaki","year":"2014","journal-title":"Mol Med Rep"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1007\/s00535-015-1054-3","article-title":"Migration of splenic lymphocytes promotes liver fibrosis through modification of T helper cytokine balance in mice","volume":"50","author":"Tanabe","year":"2015","journal-title":"J Gastroenterol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"1746391","DOI":"10.1155\/2018\/1746391","article-title":"Host immunological effects of partial splenic embolization in patients with liver cirrhosis","volume":"2018","author":"Matsukiyo","year":"2018","journal-title":"J Immunol Res"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1440-1746.2008.05497.x","article-title":"Platelets contribute to the reduction of liver fibrosis in mice","volume":"24","author":"Watanabe","year":"2009","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026441","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:34:28Z","timestamp":1746336868000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,2]]},"references-count":28,"journal-issue":{"issue":"26","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000026441","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2021,7,2]]},"assertion":[{"value":"2021-01-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}